Abelacimab, formerly known as MAA868, represents a groundbreaking approach to preventing thrombosis. This blood-thinning agent is a targeted monoclonal immunoglobulin that blocks the integrin αIIbβ3, a key player in https://myalzkc566913.blog-gold.com/57793076/abelacimab-maa868-a-deep-investigation-into-the-new-thrombosis-treatment